# WEEKLY EPIDEMIOLOGY BULLETIN

NATIONAL SURVEILLANCE UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

# Weekly Spotlight

# Safe Water Better Health

Ensuring the access of all people to sufficient, safe water and adequate sanitation and encouraging personal, domestic and community hygiene will improve the health and quality of life of millions of individuals. Adequate WASH (water, sanitation and hygiene) is essential not only to reduce the large burden of disease from, for example diarrhoea, respiratory infections and malnutrition, but also for the control and elimination of many neglected tropical diseases, which affect over 1 billion people in 149 tropical and subtropical countries. Furthermore, cholera is still endemic in at least 47 countries, with an estimated 2.9 million cases and 95 000 deaths per year worldwide.



Antimicrobial resistance (AMR) can have devastating consequences on health and the cost of treatment. In communities, access to adequate WASH contributes to reducing the risk of infectious diseases and overuse of antibiotics. Health care facilities and pharmaceutical industries that do not adequately manage their waste also contribute to AMR, and lack of adequate WASH services in health care facilities increases the risks of patients, caretakers and health care workers for infection.

Better management of water resources to reduce the transmission of vector-borne diseases, such as viral diseases carried by mosquitoes, and to make water bodies safe for recreational and other users can save many lives and also has direct and indirect economic benefits, from the level of households to national economies. The global importance of adequate WASH for development, poverty reduction and health is reflected in the Sustainable Development Goals (SDGs). SDG 6, "Ensure access to water and sanitation for all" is entirely devoted to improved WASH.

Taken from WHO website on 07/Aug/2025
https://www.who.int/publications/i/item/9789241516891
Picture taken from https://www.who.int/news-room/fact-sheets/detail/sanitation

# EPI WEEK 30



Syndromic Surveillance

Accidents


Violence

Pages 2-4



Class 1 Notifiable Events

Page 5



COVID-19

Page 6



Influenza

Page 7



**Dengue Fever** 

Page 8




Research Paper

Page 9

SENTINEL SYNDROMIC SURVEILLANCE

Sentinel Surveillance in Jamaica





Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.

Table showcasing the
Timeliness of Weekly
Sentinel Surveillance
Parish Reports for the Four
Most Recent
Epidemiological Weeks –
27 to 30 of 2025

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. Reports submitted after 3 p.m. are considered late.

### KEY:

**Yellow-** late submission on Tuesday

**Red** – late submission after Tuesday


| Epi week | Kingston and Saint<br>Andrew | Saint Thomas | Saint Catherine | Portland | Saint Mary | Saint Ann | Trelawny | Saint James | Hanover | Westmoreland | Saint Elizabeth | Manchester | Clarendon |
|----------|------------------------------|--------------|-----------------|----------|------------|-----------|----------|-------------|---------|--------------|-----------------|------------|-----------|
|          |                              |              |                 |          |            | 20        | )25      |             |         |              |                 |            |           |
| 27       | On                           | On           | On              | On       | On         | On        | On       | On          | On      | On           | On              | On         | On        |
|          | Time                         | Time         | Time            | Time     | Time       | Time      | Time     | Time        | Time    | Time         | Time            | Time       | Time      |
| 28       | Late                         | On           | On              | On       | On         | On        | On       | On          | On      | On           | On              | On         | On        |
|          | (T)                          | Time         | Time            | Time     | Time       | Time      | Time     | Time        | Time    | Time         | Time            | Time       | Time      |
| 29       | On                           | On           | On              | On       | On         | On        | On       | On          | On      | On           | On              | On         | On        |
|          | Time                         | Time         | Time            | Time     | Time       | Time      | Time     | Time        | Time    | Time         | Time            | Time       | Time      |
| 30       | On                           | On           | On              | On       | On         | On        | On       | On          | On      | On           | On              | On         | On        |
|          | Time                         | Time         | Time            | Time     | Time       | Time      | Time     | Time        | Time    | Time         | Time            | Time       | Time      |


# REPORTS FOR SYNDROMIC SURVEILLANCE

# UNDIFFERENTIATED FEVER

Temperature of  $>38^{\circ}C$  /100.4°F (or recent history of fever) with or without an obvious diagnosis or focus of infection.









INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



August 8, 2025 ISSN 0799-3927

# FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



# **FEVER AND HAEMORRHAGIC**

Temperature of  $>38^{\circ}C$ /100.40F (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.




# **FEVER AND JAUNDICE**

Temperature of  $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.


The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.




# Weekly Visits to Sentinel Sites for Fever and Neurological Symptoms 2024 and 2025 vs. Weekly Threshold: Jamaica



Weekly visits to Sentinel Sites for Fever and Haemorrhagic symptoms 2024 and 2025 vs Weekly Threshold; Jamaica



Weekly visits for Fever and Jaundice symptoms: Jamaica, Weekly Threshold vs Cases 2024 and 2025





NOTIFICATIONS-All clinical



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



**HOSPITAL ACTIVE** SURVEILLANCE-30 sites. Actively pursued






August 8, 2025 ISSN 0799-3927

# **ACCIDENTS**

Any injury for which the cause is unintentional, e.g. motor vehicle, falls, burns, etc.





# **VIOLENCE**

Any injury for which the cause is intentional, e.g. gunshot wounds, stab wounds, etc.



# Weekly Visits to Sentinel Sites for Violence by Age Groups 2025 vs. Weekly **Threshold** 800 700 Number of Visits 600 500 400 300 200 100 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 Epidemiological Week • Epi Threshold <5 y/o - Epi Threshold ≥5y/o <5 y.o ≥5 y.o

# **GASTROENTERITIS**

Inflammation of the stomach and intestines, typically resulting from bacterial toxins or viral infection and causing vomiting and diarrhoea.



# Weekly visits to Sentinel Sites for Gastroenteritis All ages 2025 vs Weekly Threshold; Jamaica 1200 1000 800 400 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 Epidemiological Week 2025 <5 2025 ≥5 Epidemic Threshold <5 Epidemic Threshold ≥5





INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



August 8, 2025 ISSN 0799-3927

# **CLASS ONE NOTIFIABLE EVENTS**

# Comments

|                                     |   |                              | Confirm               | ned YTD <sup>α</sup>                               | AFP Field Guides from   |  |  |
|-------------------------------------|---|------------------------------|-----------------------|--|---|--|--|
|                                     | CLACC 1 F   | ZVIENITO                     | CURRENT               | PREVIOUS   | WHO indicate that for an  |  |  |
| CLASS 1 EVENTS                      |   | YEAR 2025                    | YEAR 2024             | effective surveillance system, detection rates for |   |  |  |
|                                     | Accidental F  | Poisoning                    | $84^{\beta}$          | 225β   | AFP should be 1/100,000   |  |  |
| 님                                   | Cholera   |                              | 0                     | 0  | population under 15 years old (6 to 7) cases annually.                        |  |  |
| ANC                                 | Severe Deng   | gue <sup>y</sup>             | See Dengue page below | See Dengue page below                              | old (0 to 7) cases aimidally.   |  |  |
| ATI                                 | COVID-19 (  | (SARS-CoV-2)                 | 263                   | 531  | Pertussis-like syndrome and Tetanus are clinically confirmed classifications. |  |  |
| EST                                 | Hansen's Di   | sease (Leprosy)              | 0                     | 0  |   |  |  |
| L /INTERN<br>INTEREST               | Hepatitis B   |                              | 3                     | 25   |   |  |  |
| NATIONAL /INTERNATIONAL<br>INTEREST | Hepatitis C   |                              | 1                     | 8  | YDengue Hemorrhagic   |  |  |
| NO.                                 | HIV/AIDS  |                              | NA                    | NA   | Fever data include Dengue related deaths;                                     |  |  |
| IATI                                | Malaria (Im   | ported)                      | 0                     | 0  | refated deaths,   |  |  |
| Z                                   | Meningitis  |                              | 8                     | 13   | <sup>δ</sup> Figures include all deaths                                       |  |  |
|                                     | Monkeypox   |                              | 1                     | 0  | associated with pregnancy reported for the period.                            |  |  |
| EXOTIC/<br>UNUSUAL                  | Plague  |                              | 0                     | 0  | <sup>E</sup> CHIKV IgM positive case  |  |  |
| <u> </u>                            | Meningococ  | cal Meningitis               | 0                     | 0  |   |  |  |
| SH                                  | Neonatal Te   | tanus                        | 0                     | 0  | <sup>θ</sup> Zika PCR positive cases  |  |  |
| H IGH<br>MORBIDITY,<br>MORTALITY    | Typhoid Fev   | ver                          | 0                     | 0  | <sup>β</sup> Updates made to prior weeks.                                     |  |  |
| MC                                  | Meningitis H  | H/Flu                        | 0                     | 0  | <sup>α</sup> Figures are cumulative   |  |  |
|                                     | AFP/Polio   |                              | 0                     | 0  | totals for all epidemiologic  |  |  |
|                                     | Congenital F  | Rubella Syndrome             | 0                     | 0  | weeks year to date.   |  |  |
| 70                                  | Congenital S  | Congenital Syphilis          |                       | 0  |   |  |  |
| MES                                 | Fever and Rash  Maternal Dea Ophthalmia M Pertussis-like Rheumatic Fe | Measles                      | 0                     | 0  |   |  |  |
| RAM                                 |   | Rubella                      | 0                     | 0  | ,   |  |  |
| .0G                                 | Maternal De   | Maternal Deaths <sup>δ</sup> |                       | 40   |   |  |  |
| C PR                                | Ophthalmia  | Neonatorum                   | 19                    | 115  |   |  |  |
| CIA                                 | Pertussis-lik   | Pertussis-like syndrome      |                       | 0  |   |  |  |
| SPEC                                | Rheumatic F   | Gever                        | 0                     | 0  |   |  |  |
|                                     | Tetanus   |                              | 2                     | 0  |   |  |  |
|                                     | Tuberculosis  | S                            | 21                    | 30   |   |  |  |
|                                     | Yellow Feve   |                              | 0                     | 0  |   |  |  |
|                                     | Chikunguny  | a <sup>ε</sup>               | 0                     | 0  |   |  |  |
|                                     | Zika Virus <sup>θ</sup>   |                              | 0                     | 0  | NA- Not Available   |  |  |







INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



August 8, 2025 ISSN 0799-3927


# COVID-19 Surveillance Update

■ Contact of a Confirmed Case

Local Transmission (Not Epi Linked)

|           |                     | COAID                 |
|-----------|---------------------|-----------------------|
| CASES     | EW 30               | Total                 |
| Confirmed | 6                   | 157700                |
| Females   | 1                   | 90854                 |
| Males     | 5                   | 66843                 |
| Age Range | 1 years to 71 years | 1 day to 108<br>years |

- \* 3 positive cases had no gender specification
- \* PCR or Antigen tests are used to confirm cases
- \* Total represents all cases confirmed from 10 Mar 2020 to the current Epi-Week.



**COVID-19 Outcomes** 

| Outcomes                      | EW 30 | Total  |
|-------------------------------|-------|--------|
| ACTIVE *2 weeks*              |       | 15     |
| DIED – COVID<br>Related       | 0     | 3885   |
| Died - NON<br>COVID           | 0     | 400    |
| Died - Under<br>Investigation | 0     | 142    |
| Recovered and discharged      | 0     | 103226 |
| Repatriated                   | 0     | 93     |
| Total                         |       | 157700 |

\*Vaccination programme March 2021 - YTD

\* Total as at current Epi week


# 3321 COVID-19 Related Deaths since March 1, 2021 - YTD Vaccination Status among COVID-19 Deaths

Import Related


**■** Under Investigation

Imported


**■ Workplace Cluster** 



COVID-19 Parish Distribution and Global Statistics



| COVID-19 WHO Global Statistics EW 27 -30 2025 |                 |        |  |  |  |
|---|-----------------|--------|--|--|--|
| Epi Week                                      | Confirmed Cases | Deaths |  |  |  |
| 27  | 32800           | 244    |  |  |  |
| 28  | 39700           | 237    |  |  |  |
| 29  | 9000            | 209    |  |  |  |
| 30  | 8900            | 168    |  |  |  |
| Total (4weeks)                                | 90400           | 858    |  |  |  |



NOTIFICATIONS-All clinical sites



**INVESTIGATION** REPORTS- Detailed Follow up for all Class One Events



**HOSPITAL ACTIVE** SURVEILLANCE-30 sites. Actively pursued




# NATIONAL SURVEILLANCE UNIT INFLUENZA REPORT

EW 30

July 20, 2025 - July 26, 2025 Epidemiological Week 30


|  | EW 30 | YTD |
|--|-------|-----|
| SARI cases                             | 5     | 276 |
| Total Influenza<br>positive<br>Samples | 0     | 169 |
| Influenza A                            | 0     | 145 |
| H1N1pdm09                              | 0     | 78  |
| H3N2                                   | 0     | 67  |
| Not subtyped                           | 0     | 0   |
| Influenza B                            | 0     | 24  |
| B lineage not determined               | 0     | 0   |
| B Victoria                             | 0     | 24  |
| Parainfluenza                          | 0     | 0   |
| Adenovirus                             | 0     | 0   |
| RSV                                    | 0     | 30  |



Epidemic Threshold 5-59

# **Epi Week Summary**

During EW 30, five (5) SARI admissions were reported.




Distribution of Influenza and Other Respiratory Viruses Under

# Caribbean Update EW 30

Influenza activity, primarily driven A(H1N1)pdm09, declined in the latest EW, with a subregional positivity rate of 12.1%. In Haiti, influenza activity remains at epidemic levels. In constrast, in Belize, Cuba, Jamaica, Barbados, and the Dominican Republic, it remains at interseasonal levels. In Guyana, influenza activity remains unchanged compared to the previous EW. RSV circulation is increasing in the subregion, with a positivity rate 10.8%, especially in Belize, Cuba and the Dominican Republic. SARS-CoV-2 activity increased compared to the previous weeks, with a subregional positivity rate of 11.9%. In Barbados, Cuba and Guyana activity decreased. In Belize, the Dominican Republic, Saint Vincent and the Grenadines and Suriname, positivity increased.

(taken from PAHO Respiratory viruses weekly report) https://www.paho.org/en/influenza-situation-report







INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events

■ B Victoria



RSV

Epidemic Threshold <5

**HOSPITAL ACTIVE** SURVEILLANCE-30 sites. Actively pursued

■ SARS-CoV-2

Positive



■ A(H3N2)

**SENTINEL** REPORT- 78 sites. Automatic reporting

■A(H1N1)pdm09

- Epidemic Threshold ≥60


August 8, 2025 ISSN 0799-3927

# Dengue Bulletin

July 20, 2025 - July 26, 2025 Epidemiological Week 30

Epidemiological Week 30





Reported suspected, probable and confirmed dengue with symptom onset in week 30 of 2025

|  | 2025* |     |  |
|--|-------|-----|--|
|  | EW 30 | YTD |  |
| Total Suspected, Probable & Confirmed Dengue Cases | 0     | 269 |  |
| Lab Confirmed Dengue cases                         | 0     | 0   |  |
| CONFIRMED Dengue Related Deaths                    | 0     | 0   |  |

### Symptoms of Dengue fever Febrile phase sudden-onset fever Critical phase hypotension headache pleural effusion ascites mouth and nose bleeding gastrointestinal bleeding muscle and joint pains Recovery phase altered level of vomitina consciousness seizures rash itching diarrhea slow heart rate

# **Points to note:**

- Dengue deaths are reported based on date of death.
- \*Figure as at July 24, 2025
- Only PCR positive dengue cases are reported as confirmed.
- IgM positive cases are classified as presumed dengue.

### (2007-2022) 4000 3500 3000 2500 2000 1500 1000 500 MAR APR MAY JUN JUL AUG NOV DEC Month of onset 2023 2024 2025

Epidemic Threshold

Suspected, probable and confirmed dengue cases for 2023-2025 versus monthly mean, alert and epidemic threshold





INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



Monthly Mean

HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



SENTINEL REPORT- 78 sites. Automatic reporting

-Alert Threshold.

August 8, 2025 ISSN 0799-3927

# **RESEARCH PAPER**

### **Abstract**

### NHRC-23-003

The prevalence of elevated blood pressure and hypertension in adolescents 10-14 years old in Kingston and St. Andrew, Jamaica—a pilot study

Royal M<sup>1</sup>, Ferguson TS<sup>2</sup>, Harrison A<sup>3</sup>

<sup>1</sup>Bustamante Hospital for Children, Kingston, Jamaica <sup>2</sup>Caribbean Institute for Health Research, University of the West Indies, Mona, Jamaica <sup>3</sup>Department of Child and Adolescent Health, Faculty of Medical Sciences, University of the West Indies, Mona, Jamaica

**Objectives:** This study aimed to determine the prevalence of elevated blood pressure (EBP) and hypertension (HTN) in early adolescents (10-14 years) in the Kingston metropolitan area and investigate associated sociodemographic and anthropometric factors.

**Methods:** A cross-sectional study was conducted in randomly selected schools in the Kingston metropolitan region. Requisite consent and assent were obtained with institution approvals. Participants completed self-administered questionnaires collecting sociodemographic data, medical and family histories. Participants' weight, height, and blood pressure were measured using standardized procedures. Logistic regression was used to evaluate factors associated with prevalent EBP (SBP and/or DBP  $\geq$  90th < 95th percentile for sex, age, and height). Obesity is defined as a BMI  $\geq$ 95<sup>th</sup> percentile. Statistical significance was at the 5% level.

**Results:** Two hundred and seventy-six adolescents participated (male: n=123, 44.6%, mean (SD) age 11.34 (1.20) y; female: n=153, 55.4%; mean (SD) age 11.67 (1.20) y). Most participants (n=213, 77.7%) visited the doctor or nurse in the past year; 39% (n=106) had checked their BP in the past 12 months. Participants' nutritional status was categorised as underweight (n=6, 2.2%); normal weight (n=165, 59.8%); overweight (n=46, 16.7%); and obesity (n=59, 21.4%).

Five participants (n=3 males, 2 females; 1.8%) met criteria for systolic hypertension (4<sup>th</sup> report). Overweight/obesity was the only variable significantly associated with hypertension (OR 4.1, 95%CI 1.42-11.91; p<0.01) in early adolescents.

**Conclusion:** Elevated blood pressure and hypertension are health concerns for early Jamaican adolescents and are positively correlated with overweight or obesity. Suboptimal screening of BP by health care providers occurs and should be encouraged.



The Ministry of Health and Wellness *15 Knutsford Boulevard*, Kingston 5, Jamaica Tele: (876) 633-7924

Email: surveillance@moh.gov.jm



NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

